Today, Joint Resolution No. 1/2020 issued by the Ministry of Health and the Secretary of Domestic Trade (“RC 1/2020”) was published in the Official Gazette, establishing, for 150 calendar days, maximum sale prices on drugs for the treatment of COVID-19 i.e., Atracurium, Pancuronium Bromide, Fentanyl, Midazolam and Propofol, and on non-detailed presentations of these active principles.

Also, RC 1/2020 compels companies involved in the production, distribution and marketing chain of these drugs, to increase their production to the maximum of their installed capacity and to arbitrate measures to ensure their transportation, distribution and marketing throughout the country during the period of the health emergency.

Finally, RC 1/2020 imposes the obligation to laboratories that produce, prepare and/or are authorized to commercialize the products reached by RC 1/2020, to inform the National Administration of Medicines, Foods and Medical Technology (ANMAT) and the Ministry of Health, its maximum production capacity.

The RC 1/2020 entered into force today and its non-compliance will be sanctioned in accordance with the provisions set forth in Law No. 20,680 (Supply Law).

If you have any questions, please contact us:


Share on facebook
Share on twitter
Share on linkedin

More News

Write Us

Upcoming Webinars & other Events